T-cell antigen-directed bispecific molecules for immunotherapies of malignant tumors


PRINCIPLE INVESTIGATORS:
Prof. Dr. med. Ulrich Keilholz, Prof. Dr. rer. nat. Gerald Willimsky
Charité

ATMP
Oncology

2023

TRACK 2

SUMMARY

Immune-mobilizing monoclonal naturally optimized T-cell receptors (ImmnoTCRs) against cancer utilize a type of immunotherapy designed to leverage the body's immune system to target and eliminate cancer cells. These molecules bind to tumor-specific antigens and simultaneously activate local T cells, triggering a directed immune response against the cancer cells.
This project focuses on developing novel, high-affinity ImmnoTCRs targeting various types of cancer.
Promising candidate ImmnoTCRs will undergo preclinical testing, including evaluations using patient-derived organoid models, before advancing to clinical trials.

PROJECT GOALS

- To select one lead candidate with optimal efficacy for clinical testing.
- Establish the regulatory framework and design of an initial clinical study.

LONG-TERM GOALS

- Clinical validation
- Develop an efficacious treatment